Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Phio Pharmaceuticals ( (PHIO) ) has provided an announcement.
On March 30, 2026, Phio Pharmaceuticals announced it had signed a cGMP drug product manufacturing services agreement with a U.S. manufacturer to secure clinical supply. The move underscores the company’s efforts to advance its pipeline into, or through, clinical development by locking in compliant production capacity, a step that may help streamline trial readiness and strengthen its operational footing in the competitive biotech landscape.
The most recent analyst rating on (PHIO) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Phio Pharmaceuticals stock, see the PHIO Stock Forecast page.
Spark’s Take on PHIO Stock
According to Spark, TipRanks’ AI Analyst, PHIO is a Neutral.
The score is held down primarily by weak financial performance (no revenue, ongoing losses, and meaningful cash burn), partially offset by a stronger balance sheet with no debt and increased equity. Technicals are mixed (short-term improvement vs. longer-term downtrend). Corporate events are a clear positive due to encouraging PH-762 safety/response data and regulatory progress, while valuation remains constrained by negative earnings.
To see Spark’s full report on PHIO stock, click here.
More about Phio Pharmaceuticals
Phio Pharmaceuticals Corp. is a biotechnology company focused on developing pharmaceutical drug products. The company operates in the life sciences sector, where it advances clinical-stage candidates and relies on specialized manufacturing partners to produce cGMP-compliant drug supplies for use in human studies and regulatory-driven development programs.
Average Trading Volume: 3,893,975
Technical Sentiment Signal: Sell
Current Market Cap: $14.64M
Learn more about PHIO stock on TipRanks’ Stock Analysis page.